Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.
Wykrzykowska JJ, Kraak RP, Hofma SH, van der Schaaf RJ, Arkenbout EK, IJsselmuiden AJ, Elias J, van Dongen IM, Tijssen RYG, Koch KT, Baan J Jr, Vis MM, de Winter RJ, Piek JJ, Tijssen JGP, Henriques JPS; AIDA Investigators. Wykrzykowska JJ, et al. Among authors: tijssen jgp, tijssen ryg. N Engl J Med. 2017 Jun 15;376(24):2319-2328. doi: 10.1056/NEJMoa1614954. Epub 2017 Mar 29. N Engl J Med. 2017. PMID: 28402237 Free article. Clinical Trial.
Mid-term and long-term safety and efficacy of bioresorbable vascular scaffolds versus metallic everolimus-eluting stents in coronary artery disease: A weighted meta-analysis of seven randomised controlled trials including 5577 patients.
Elias J, van Dongen IM, Kraak RP, Tijssen RYG, Claessen BEPM, Tijssen JGP, de Winter RJ, Piek JJ, Wykrzykowska JJ, Henriques JPS. Elias J, et al. Among authors: tijssen jgp, tijssen ryg. Neth Heart J. 2017 Jul;25(7-8):429-438. doi: 10.1007/s12471-017-1008-x. Neth Heart J. 2017. PMID: 28612280 Free PMC article.
Evaluation of the MiStent sustained sirolimus eluting biodegradable polymer coated stent for the treatment of coronary artery disease: does uniform sustained abluminal drug release result in earlier strut coverage and better safety profile?
Tijssen RYG, Kraak RP, Lu H, Mifek JG, Carlyle WC, Donohoe DJ, De Winter RJ, Koch KT, Wykrzykowska JJ. Tijssen RYG, et al. Expert Rev Med Devices. 2017 May;14(5):325-334. doi: 10.1080/17434440.2017.1318057. Epub 2017 Apr 24. Expert Rev Med Devices. 2017. PMID: 28402204 Review.
The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial.
Tijssen RYG, Kerkmeijer LSM, Katagiri Y, Kraak RP, Takahashi K, Kogame N, Chichareon P, Modolo R, Asano T, Nassif M, Kalkman DN, Sotomi Y, Collet C, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers APJD, Beijk MAM, Piek JJ, Tijssen JGP, Henriques JP, de Winter RJ, Onuma Y, Serruys PW, Wykrzykowska JJ. Tijssen RYG, et al. Int J Cardiovasc Imaging. 2019 Jul;35(7):1189-1198. doi: 10.1007/s10554-019-01576-y. Epub 2019 Mar 25. Int J Cardiovasc Imaging. 2019. PMID: 30911857 Free PMC article. Clinical Trial.
The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy.
Tijssen RYG, Kerkmeijer LSM, Takahashi K, Kogame N, Katagiri Y, Kraak RP, Chichareon P, Modolo R, Asano T, Nassif M, Kalkman DN, Sotomi Y, Collet C, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers APJD, Piek JJ, Tijssen JGP, Henriques JP, de Winter RJ, Onuma Y, Serruys PW, Wykrzykowska JJ. Tijssen RYG, et al. Int J Cardiovasc Imaging. 2020 Apr;36(4):565-575. doi: 10.1007/s10554-019-01756-w. Epub 2020 Jan 2. Int J Cardiovasc Imaging. 2020. PMID: 31898006 Clinical Trial.
Three-year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus-eluting stent in routine PCI in patients with diabetes mellitus-AIDA sub-study.
Kerkmeijer LSM, Tijssen RYG, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers APJD, Kraak RP, Onuma Y, Serruys PW, Piek JJ, Tijssen JGP, Henriques JPS, de Winter RJ, Wykrzykowska JJ. Kerkmeijer LSM, et al. Among authors: tijssen ryg. Catheter Cardiovasc Interv. 2021 Oct;98(4):713-720. doi: 10.1002/ccd.29329. Epub 2020 Oct 29. Catheter Cardiovasc Interv. 2021. PMID: 33118696 Free PMC article. Clinical Trial.
Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease-AIDA trial substudy.
Tijssen RYG, van der Schaaf RJ, Kraak RP, Vink MA, Hofma SH, Arkenbout EK, Weevers APJD, Kerkmeijer LSM, Onuma Y, Serruys PW, Beijk MAM, Koch KT, Baan J Jr, Vis MM, Piek JJ, Tijssen JGP, Henriques JPS, de Winter RJ, Wykrzykowska JJ. Tijssen RYG, et al. Catheter Cardiovasc Interv. 2020 Jan;95(1):89-96. doi: 10.1002/ccd.28193. Epub 2019 Apr 9. Catheter Cardiovasc Interv. 2020. PMID: 30968559 Clinical Trial.
A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trial.
Kerkmeijer LSM, Tijssen RYG, Hofma SH, Pinxterhuis TH, Kraak RP, Kalkman DN, van der Schaaf RJ, Arkenbout EK, Weevers APJD, Beijk MA, Baan J Jr, Vis MM, Koch KT, Tijssen JGP, Piek JJ, Henriques JPS, de Winter RJ, Wykrzykowska JJ. Kerkmeijer LSM, et al. Among authors: tijssen ryg. Int J Cardiol. 2020 Feb 1;300:93-98. doi: 10.1016/j.ijcard.2019.08.045. Epub 2019 Aug 30. Int J Cardiol. 2020. PMID: 31511193 Free article. Clinical Trial.
Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial.
Kerkmeijer LSM, Renkens MPL, Tijssen RYG, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers APJD, Garcia-Garcia HM, Kraak R, Piek JJ, Tijssen JGP, Henriques JPS, de Winter RJ, Wykrzykowska JJ. Kerkmeijer LSM, et al. Among authors: tijssen ryg. EuroIntervention. 2022 Mar 18;17(16):1340-1347. doi: 10.4244/EIJ-D-21-00419. EuroIntervention. 2022. PMID: 34483094 Free PMC article. Clinical Trial.
21 results